Access Biotechnology led Hemab Therapeutics’ $135m series B round while South Africa's Sasol launched a $53m CVC partnership with Emerald Technology Ventures.

Person Holding Medicines

Funds

South African chemicals and energy group Sasol formed a €50m ($53.3m) corporate venturing arm dubbed Sasol Ventures that will be managed by Switzerland-headquartered venture capital firm Emerald Technology Ventures as investment adviser. Sasol Ventures will target sustainable chemicals and energy technologies that can decarbonise its operations.

Japan-based venture capital firm Animal Spirits has secured limited partners including taxi and limousine operator Nihon Kotsu and leasing…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in